Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline

Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline

August 15, 2007

Research by CMR Shows Revenue Derived from New Products
Launched within the Last Five Years has Dropped to Just 16%
of Total Revenue in 2006


    PHILADELPHIA, Aug. 15 /Xinhua-PRNewswire/ -- Thomson
Scientific, part of The Thomson Corporation (NYSE: TOC;
TSX: TOC) and leading provider of information solutions to
the worldwide research and business communities, today
issued its quarterly The Ones-to-Watch report, providing
expert insight into the five most promising drugs to enter
each new phase of clinical development between April and
June 2007.

    "This quarter's most promising drugs all have
significant market potential and are associated with
diseases and conditions that impact countless numbers of
individuals," said Peter Robins, PhD, and editorial
content manager, Thomson Scientific. "These important
clinical developments are highly encouraging for
innovation-based companies in a period when many
pharmaceutical products are coming toward the end of their
patent protection."

    New research from CMR, a Thomson company, shows that
revenue derived from new products (those launched within
the last five years) dropped to just 16% of total revenue
in 2006. And although the cost of research and development
continues to rise, there is no sign of a sustained upturn
in the number of new products reaching the market.

    Which are the Ones-to-Watch this Quarter?

    Topping this quarter's approval list is Novartis
Vaccines & Diagnostics' Optaflu(R), a vaccine for
influenza derived from a novel, proprietary cell line.
Approved for use in the EU in June 2007, Novartis plans to
file for US approval of Optaflu in 2008. 

    Second on our list is Wyeth, which is marketing
Lybrel(TM) -- a combination of Ievonorgestrel and ethinyl
estradiol in a daily oral tablet which eliminates the
menstrual cycle and is being trialed as a potential
treatment for severe premenstrual syndromes. 

    Third is a drug launched in Japan in June 2007 for the
treatment of incontinence and pollakiuria (frequent
urination) under the name Staybla(R).  Urinary incontinence
is particularly prevalent in men and usually associated with
aging. Where the problem is an overactive bladder, patients
may benefit from the M1 and M3 muscarinic receptor
imidafenacin, developed by Kyorin Pharmaceutical, Ono
Pharmaceutical and LG Life Sciences. 

    Fourth is a drug for one of the most severe forms of
epilepsy (Lennox-Gastaut Syndrome or LGS), affecting
approximately 5% of the children who have the disease.
Eisai's rufinamide, licensed from Novartis, is the first
drug approved in the EU specifically for LGS. Eisai
launched rufinamide in Germany, Australia and Scandinavia
in June 2007 under the name Inovelon(TM). US filing is in
process.

    Finally for this section this quarter, Torisel(TM) is
the brand name of temsirolimus, an analog of the mTOR
inhibitor sirolimus (rapamycin) developed by Wyeth Research
for the oral treatment of advanced renal cell carcinoma
(RRC). Having received FDA approval in May 2007, the drug
is now available to patients in the US, while approval is
pending in the EU.

    Following are the top five drugs in each category of
phase changes:

    The Five Most Promising Drugs Entering Phase III Trials
    - trazodone, (Depression), Labopharm
    - pimavanserin, (Schizophrenia), ACADIA Pharmaceuticals
    - salmon calcitonin, (Osteoporosis/Paget's disease),
Novartis/Nordic
      Bioscience
    - Generx(TM), (Coronary artery disease), Cardium
Therapeutics
    - fenofibrate and pravastatin, (Mixed dyslipidemia),
Sciele
      Pharma/Galephar PR

    The Five Most Promising Drugs Entering Phase II Trials
    - VSF-173, (Excessive sleepiness), Vanda
Pharmaceuticals
    - APD-125, (Insomnia), Arena
    - Neugranin(TM), (Chemotherapy-induced neutropenia),
CoGenesys
    - Hepaconda(R) , (Hepatitis C), Giaconda
    - GRC-6211, (Pain), Glenmark

    The Five Most Promising Drugs Entering Phase I Trials
    - Ad35 HIV-ENvA, (HIV infection), GenVec/NIAID Vaccine
Research Center
    - nestorone and estradiol (transdermal gel), (Female
contraception),
      Antares/Population Council
    - Fluvacc, (Influenza), Avir Green Hills Biotechnology
    - insulin oral gel capsule, (Diabetes), Oramed
    - trodusquemine, (Obesity), Ganaera

    About This Quarterly Report:

    Data for this report was compiled and analyzed using
Thomson Pharma(R), a comprehensive global pharmaceutical
information solution that covers the entire drug discovery
and development pipeline. Its competitive intelligence and
strategic data can justify and speed decision-making,
facilitate more focused collaboration, and encourage
innovation. 

    For a copy of the full report with analysis, visit:
http://www.thomsonpharma.com/media/pdfs/tpqr/tp_qr_apr2007.pdf

    About The Thomson Corporation

    The Thomson Corporation ( http://www.thomson.com ) is a
global leader in providing essential electronic workflow
solutions to business and professional customers.  With
operational headquarters in Stamford, Conn., Thomson
provides value-added information, software tools and
applications to professionals in the fields of law, tax,
accounting, financial services, scientific research and
healthcare.  The Corporation's common shares are listed on
the New York and Toronto stock exchanges (NYSE: TOC; TSX:
TOC). 

    Thomson Scientific is a business of The Thomson
Corporation.  Its information solutions assist
professionals at every stage of research and
development-from discovery to analysis to product
development and distribution. Thomson Scientific
information solutions can be found at
scientific.thomson.com.






    For more information, please contact:

     Allison Hagan 
     Thomson Scientific
     Tel:   [phone]
     Email: [e-mail]